Microencapsulation for Enhanced Bioavailability of Fish Oil - Acute Study
Microencapsulation for Enhanced Bioavailability of Fish Oil in Healthy Adult Volunteers - Acute Study
CSIRO Preventative Health Flagship
15 participants
Oct 18, 2010
Interventional
Conditions
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This study will compare the short term bioavailability of 3 delivery systems containing omega-3 oils. They are (1) gel capsules versus (2) MicroMAX 1 powder – formulated with milk protein-sugar versus (3) MicroMAX powder - formulated with milk protein-sugar-resistant starch) when combined with a flavoured milk in individuals. Bioavailability will be assessed by measurement of EPA & DHA in blood/plasma. This is a crossover design study in which all participants will receive the three treatments with a washout period of 6 weeks between each treatment. To investigate the bioavailability of a single dose of omega-3 oils delivered via the three above mentioned formats over 48 hrs. The two different MicroMAX powders (one formulated with milk protein-sugar and other milk protein-sugar-resistant starch) will each be provided as an 8g serve containing a dose of 500mg/g omega-3 oil. The gel capsules will be given as a one-off dose of 4 capsules (each capsule will contain 1000mg of omega-3 oil).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000012976